Cargando…
Targeting hyperactive TGFBR2 for treating MYOCD deficient lung cancer
Purpose: Clinical success of cancer therapy is severely limited by drug resistance, attributed in large part to the loss of function of tumor suppressor genes (TSGs). Developing effective strategies to treat those tumors is challenging, but urgently needed in clinic. Experimental Design: MYOCD is a...
Autores principales: | Zhou, Qian, Chen, Wensheng, Fan, Zhenzhen, Chen, Zhipeng, Liang, Jinxia, Zeng, Guandi, Liu, Lu, Liu, Wanting, Yang, Tong, Cao, Xin, Yu, Biao, Xu, Meng, Chen, Ye-Guang, Chen, Liang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Ivyspring International Publisher
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8120205/ https://www.ncbi.nlm.nih.gov/pubmed/33995678 http://dx.doi.org/10.7150/thno.59816 |
Ejemplares similares
-
Lung cancer deficient in the tumor suppressor GATA4 is sensitive to TGFBR1 inhibition
por: Gao, Lei, et al.
Publicado: (2019) -
GATA6 Exerts Potent Lung Cancer Suppressive Function by Inducing Cell Senescence
por: Chen, Wensheng, et al.
Publicado: (2020) -
Inactivation of tumor suppressor gene Clusterin leads to hyperactivation of TAK1-NF-κB signaling axis in lung cancer cells and denotes a therapeutic opportunity
por: Chen, Zhipeng, et al.
Publicado: (2020) -
Myocd regulates airway smooth muscle cell remodeling in response to chronic asthmatic injury
por: Yang, Qin, et al.
Publicado: (2023) -
In vivo genome-wide CRISPR screening identifies ZNF24 as a negative NF-κB modulator in lung cancer
por: Liu, Lu, et al.
Publicado: (2022)